BMO Capital Markets analyst Evan Seigerman said Pfizer’s discontinuation of its GLP-1 pill sends the company back to the starting block as its other obesity drugs are all in the early stages of ...

Scientifically Designed 4-Stage Fat Loss Supplement Offers Safe, Non-Prescription Alternative to GLP-1 Drugs Like ...

Weight Watchers has outlasted diet fads, rebrands and even logic. But this time, it’s not carbs or keto that brought it down ...

So far this year, Pfizer shares have dropped 17.4%, while Novo Nordisk's stock has tumbled 24% and Lilly shares have slipped 3.2%. The SPDR S&P Pharmaceuticals ETF XPH has shed 12.1% year to date and ...

Shares of Structure Therapeutics Inc ADR (NASDAQ: GPCR) climbed 6.8% following the news that Pfizer Inc. (NYSE: NYSE:PFE) has ...

The implications for Eli Lilly and Novo Nordisk seem pretty clear: The immediate removal of a rival for the massive revenues ...

Viking Therapeutics enjoyed a nice share rally on the news that rival Pfizer is discontinuing obesity candidate danuglipron.

Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid ...

Shares of Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are on the rise on Monday after Pfizer (PFE) announced its decision to ...

From STAT’s Matthew Herper: Pfizer said this morning that it would stop development of danuglipron, its experimental oral GLP ...

Pfizer halted development of its weight-loss pill, danuglipron, after liver injury concerns surfaced during trials, impacting ...

Pfizer on Monday said it has discontinued development of experimental weight-loss pill danuglipron after a trial patient ...